Search results
PROMOTED
How do worsening heart events dictate the long-term outcomes of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and can earlier intervention influence the disease trajectory in ATTR-CM? In this new sub-analysis from ATTRibute-CM, recorded onsite at ESC Heart Failure Congress (HFA) 2026, Prof Marianna Fontana (University College London, London, UK) sheds further light onto these…
View more
HFA 2026: Updates on ATTR-CM
Author(s):
Marianna Fontana
,
Added:
1 month ago
Video Series
Author(s):
Maria Fernández García
,
Beatriz Nieves Ureña
,
Alberto Alen Andrés
,
et al
Added:
2 months ago
Author(s):
Mohammed Sallam
,
Hossameldin Hassan
,
Derek Connolly
,
et al
Added:
1 year ago
Author(s):
Raúl Ludeña
,
Raúl Ptaszynski Lanza
,
Francisco González
,
et al
Added:
2 months ago
Ibrutinib, Venetoclax and Adverse Cardiovascular Events
Author(s):
Roberta Esposito
,
Pierantonio Menna
,
Emanuela Salvatorelli
,
et al
Added:
8 months ago
Expert Opinion
Factor XIa Inhibitors’ Future Position in AF
Author(s):
Maki Komiyama
,
Moritake Iguchi
,
Hiromichi Wada
,
et al
Added:
1 year ago
Expert Opinion
Author(s):
Renato D Lopes
Added:
1 year ago
ESC Congress 24 — AF screening with a wearable ECG device increases diagnosis by over 50% but did not significantly reduce hospitalisation rates for stroke.We are joined onsite at ESC Congress 2024 by Dr Renato Lopes (Duke University Medical Center, NC) to discuss the findings from the GUARD-AF Trial (NCT04126486, Bristol-Myers Squibb), which was designed to determine if screening for undiagnosed…
View more
Author(s):
Benoit Mores
Added:
7 months ago
Revascularisation in Patients with Cancer
Author(s):
Miguel Nobre Menezes
,
Mamas A Mamas
Added:
4 months ago
Review Article
Author(s):
Kausik Ray
,
Upendra Kaul
,
Srinivasa Rao
,
et al
Added:
6 months ago